Country
United States
Cancer incidence and mortality for United States as published by the source registry: per site group, per year and sex, with age-standardized rates where the source provides them. Population statistics describe groups, never individuals.
- ISO 3166-1
- USA · US
- WHO region
- WHO Region of the Americas
- Population
- not seeded — CancerIndex shows only rates and counts published by the source
- Years covered
- 1999–2024
- Cancer entities
- 36
- Estimate types
- observed
Summary
2003 · Female · all ages
Totals across all cancer sites are shown only when the source publishes an all-sites row. Otherwise the per-site figures below stand on their own; CancerIndex never sums site groups (definitions overlap between sources).
- Deathshighest site group:Malignant Lung Neoplasm68,084countcdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
- New caseshighest site group:Malignant Breast Neoplasm195,637countcdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
- Mortality rate (age-standardized)highest site group:Malignant Lung Neoplasm41.3per 100,000cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
- Incidence rate (age-standardized)highest site group:Malignant Breast Neoplasm122.9per 100,000cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
No all-sites total in source for this scope — per-site figures below; no national total is computed.
Top cancers
By deaths
2003 · Female · all ages · 28 site groups
| # | Cancer | Deaths (count) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Lung NeoplasmCancer | 68,084 | — | observed | #1 of 28 | USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349) | cdc-uscsObserved |
| 2 | Malignant Breast NeoplasmCancer Family | 41,619 | — | observed | #2 of 28 | USCS "Female Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 3 | Malignant Colon NeoplasmCancer | 23,998 | — | observed | #3 of 28 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 4 | Malignant Pancreatic NeoplasmCancer | 15,717 | — | observed | #4 of 28 | USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259) | cdc-uscsObserved |
| 5 | Malignant Ovarian NeoplasmCancer | 14,657 | — | observed | #5 of 28 | USCS "Ovary" (ICD-10 C56; ICD-O-3 C569) | cdc-uscsObserved |
| 6 | Non-Hodgkin LymphomaHematologic Malignancy | 10,076 | — | observed | #6 of 28 | USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood)) | cdc-uscsObserved |
| 7 | LeukemiaCancer Family | 9,504 | — | observed | #7 of 28 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 8 | Malignant Central Nervous System NeoplasmCancer | 5,779 | — | observed | #8 of 28 | USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729) | cdc-uscsObserved |
| 9 | Malignant Liver NeoplasmCancer | 5,224 | — | observed | #9 of 28 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 10 | Multiple MyelomaHematologic Malignancy | 5,221 | — | observed | #10 of 28 | USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734) | cdc-uscsObserved |
| 11 | Malignant Gastric NeoplasmCancer | 5,055 | — | observed | #11 of 28 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 12 | Malignant Kidney NeoplasmCancer | 4,619 | — | observed | #12 of 28 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 13 | Malignant Cervical NeoplasmCancer | 3,919 | — | observed | #13 of 28 | USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539) | cdc-uscsObserved |
| 14 | Malignant Bladder NeoplasmCancer | 3,907 | — | observed | #14 of 28 | USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679) | cdc-uscsObserved |
| 15 | Malignant Rectal NeoplasmCancer | 3,795 | — | observed | #15 of 28 | USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209) | cdc-uscsObserved |
| 16 | Malignant Uterine Corpus NeoplasmCancer | 3,261 | — | observed | #16 of 28 | USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549) | cdc-uscsObserved |
| 17 | Malignant Esophageal NeoplasmCancer | 2,939 | — | observed | #17 of 28 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 18 | Cutaneous MelanomaCancer | 2,855 | — | observed | #18 of 28 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 19 | Malignant Thyroid Gland NeoplasmCancer | 779 | — | observed | #19 of 28 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 20 | Malignant Vulvar NeoplasmCancer | 775 | — | observed | #20 of 28 | USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519) | cdc-uscsObserved |
| 21 | Malignant Laryngeal NeoplasmCancer | 771 | — | observed | #21 of 28 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 22 | Hodgkin LymphomaHematologic Malignancy | 622 | — | observed | #22 of 28 | USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal)) | cdc-uscsObserved |
| 23 | Malignant MesotheliomaCancer Family | 469 | — | observed | #23 of 28 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 24 | Malignant Vaginal NeoplasmCancer | 391 | — | observed | #24 of 28 | USCS "Vagina" (ICD-10 C52; ICD-O-3 C529) | cdc-uscsObserved |
| 25 | Malignant Anal NeoplasmCancer | 369 | — | observed | #25 of 28 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
| 26 | Malignant Salivary Gland NeoplasmCancer | 259 | — | observed | #26 of 28 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 27 | Malignant Nasopharyngeal NeoplasmCancer | 193 | — | observed | #27 of 28 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 28 | Malignant Hypopharyngeal NeoplasmCancer | 67 | — | observed | #28 of 28 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Top cancers
By new cases
2003 · Female · all ages · 29 site groups
| # | Cancer | New cases (count) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Breast NeoplasmCancer Family | 195,637 | — | observed | #1 of 29 | USCS "Female Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 2 | Malignant Lung NeoplasmCancer | 91,135 | — | observed | #2 of 29 | USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349) | cdc-uscsObserved |
| 3 | Malignant Colon NeoplasmCancer | 57,622 | — | observed | #3 of 29 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 4 | Malignant Uterine Corpus NeoplasmCancer | 35,823 | — | observed | #4 of 29 | USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549) | cdc-uscsObserved |
| 5 | Non-Hodgkin LymphomaHematologic Malignancy | 27,102 | — | observed | #5 of 29 | USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood)) | cdc-uscsObserved |
| 6 | Malignant Ovarian NeoplasmCancer | 21,800 | — | observed | #6 of 29 | USCS "Ovary" (ICD-10 C56; ICD-O-3 C569) | cdc-uscsObserved |
| 7 | Cutaneous MelanomaCancer | 21,614 | — | observed | #7 of 29 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 8 | Malignant Thyroid Gland NeoplasmCancer | 19,748 | — | observed | #8 of 29 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 9 | Malignant Rectal NeoplasmCancer | 17,851 | — | observed | #9 of 29 | USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209) | cdc-uscsObserved |
| 10 | LeukemiaCancer Family | 17,047 | — | observed | #10 of 29 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 11 | Malignant Pancreatic NeoplasmCancer | 17,004 | — | observed | #11 of 29 | USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259) | cdc-uscsObserved |
| 12 | Malignant Bladder NeoplasmCancer | 16,330 | — | observed | #12 of 29 | USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679) | cdc-uscsObserved |
| 13 | Malignant Kidney NeoplasmCancer | 16,226 | — | observed | #13 of 29 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 14 | Malignant Cervical NeoplasmCancer | 12,707 | — | observed | #14 of 29 | USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539) | cdc-uscsObserved |
| 15 | Malignant Central Nervous System NeoplasmCancer | 9,083 | — | observed | #15 of 29 | USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729) | cdc-uscsObserved |
| 16 | Malignant Gastric NeoplasmCancer | 8,360 | — | observed | #16 of 29 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 17 | Multiple MyelomaHematologic Malignancy | 8,109 | — | observed | #17 of 29 | USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734) | cdc-uscsObserved |
| 18 | Malignant Liver NeoplasmCancer | 4,973 | — | observed | #18 of 29 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 19 | Malignant Vulvar NeoplasmCancer | 3,839 | — | observed | #19 of 29 | USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519) | cdc-uscsObserved |
| 20 | Hodgkin LymphomaHematologic Malignancy | 3,768 | — | observed | #20 of 29 | USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal)) | cdc-uscsObserved |
| 21 | Malignant Esophageal NeoplasmCancer | 3,352 | — | observed | #21 of 29 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 22 | Malignant Anal NeoplasmCancer | 2,729 | — | observed | #22 of 29 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
| 23 | Malignant Laryngeal NeoplasmCancer | 2,556 | — | observed | #23 of 29 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 24 | Malignant Salivary Gland NeoplasmCancer | 1,450 | — | observed | #24 of 29 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 25 | Malignant Vaginal NeoplasmCancer | 1,156 | — | observed | #25 of 29 | USCS "Vagina" (ICD-10 C52; ICD-O-3 C529) | cdc-uscsObserved |
| 26 | Malignant MesotheliomaCancer Family | 690 | — | observed | #26 of 29 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 27 | Malignant Nasopharyngeal NeoplasmCancer | 539 | — | observed | #27 of 29 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 28 | Malignant Hypopharyngeal NeoplasmCancer | 450 | — | observed | #28 of 29 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
| 29 | Kaposi SarcomaCancer | 184 | — | observed | #29 of 29 | USCS "Kaposi Sarcoma" (ICD-10 C46; ICD-O-3 histology 9140 (any site)) | cdc-uscsObserved |
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Top cancers
By mortality rate (age-standardized)
2003 · Female · all ages · 28 site groups · 2000 U.S. standard population (19 age groups)
| # | Cancer | Mortality rate (age-standardized) (per 100,000) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Lung NeoplasmCancer | 41.3 | 41–41.6 | observed | #1 of 28 | USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349) | cdc-uscsObserved |
| 2 | Malignant Breast NeoplasmCancer Family | 25.3 | 25–25.5 | observed | #2 of 28 | USCS "Female Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 3 | Malignant Colon NeoplasmCancer | 14 | 13.8–14.1 | observed | #3 of 28 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 4 | Malignant Pancreatic NeoplasmCancer | 9.3 | 9.1–9.4 | observed | #4 of 28 | USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259) | cdc-uscsObserved |
| 5 | Malignant Ovarian NeoplasmCancer | 8.9 | 8.7–9 | observed | #5 of 28 | USCS "Ovary" (ICD-10 C56; ICD-O-3 C569) | cdc-uscsObserved |
| 6 | Non-Hodgkin LymphomaHematologic Malignancy | 5.9 | 5.8–6 | observed | #6 of 28 | USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood)) | cdc-uscsObserved |
| 7 | LeukemiaCancer Family | 5.6 | 5.5–5.7 | observed | #7 of 28 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 8 | Malignant Central Nervous System NeoplasmCancer | 3.6 | 3.5–3.7 | observed | #8 of 28 | USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729) | cdc-uscsObserved |
| 9 | Malignant Liver NeoplasmCancer | 3.1 | 3–3.2 | observed | #9 of 28 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 10 | Multiple MyelomaHematologic Malignancy | 3.1 | 3–3.2 | observed | #9 of 28 | USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734) | cdc-uscsObserved |
| 11 | Malignant Gastric NeoplasmCancer | 3 | 2.9–3.1 | observed | #11 of 28 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 12 | Malignant Kidney NeoplasmCancer | 2.7 | 2.7–2.8 | observed | #12 of 28 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 13 | Malignant Cervical NeoplasmCancer | 2.5 | 2.4–2.6 | observed | #13 of 28 | USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539) | cdc-uscsObserved |
| 14 | Malignant Bladder NeoplasmCancer | 2.2 | 2.2–2.3 | observed | #14 of 28 | USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679) | cdc-uscsObserved |
| 15 | Malignant Rectal NeoplasmCancer | 2.2 | 2.2–2.3 | observed | #14 of 28 | USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209) | cdc-uscsObserved |
| 16 | Malignant Uterine Corpus NeoplasmCancer | 2 | 1.9–2 | observed | #16 of 28 | USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549) | cdc-uscsObserved |
| 17 | Cutaneous MelanomaCancer | 1.7 | 1.7–1.8 | observed | #17 of 28 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 18 | Malignant Esophageal NeoplasmCancer | 1.7 | 1.7–1.8 | observed | #17 of 28 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 19 | Malignant Laryngeal NeoplasmCancer | 0.5 | 0.4–0.5 | observed | #19 of 28 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 20 | Malignant Thyroid Gland NeoplasmCancer | 0.5 | 0.4–0.5 | observed | #19 of 28 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 21 | Hodgkin LymphomaHematologic Malignancy | 0.4 | 0.4–0.4 | observed | #21 of 28 | USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal)) | cdc-uscsObserved |
| 22 | Malignant Vulvar NeoplasmCancer | 0.4 | 0.4–0.5 | observed | #21 of 28 | USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519) | cdc-uscsObserved |
| 23 | Malignant MesotheliomaCancer Family | 0.3 | 0.3–0.3 | observed | #23 of 28 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 24 | Malignant Anal NeoplasmCancer | 0.2 | 0.2–0.2 | observed | #24 of 28 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
| 25 | Malignant Salivary Gland NeoplasmCancer | 0.2 | 0.1–0.2 | observed | #24 of 28 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 26 | Malignant Vaginal NeoplasmCancer | 0.2 | 0.2–0.3 | observed | #24 of 28 | USCS "Vagina" (ICD-10 C52; ICD-O-3 C529) | cdc-uscsObserved |
| 27 | Malignant Nasopharyngeal NeoplasmCancer | 0.1 | 0.1–0.1 | observed | #27 of 28 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 28 | Malignant Hypopharyngeal NeoplasmCancer | 0 | 0–0.1 | observed | #28 of 28 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Top cancers
By incidence rate (age-standardized)
2003 · Female · all ages · 29 site groups · 2000 U.S. standard population (19 age groups)
| # | Cancer | Incidence rate (age-standardized) (per 100,000) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Breast NeoplasmCancer Family | 122.9 | 122.4–123.5 | observed | #1 of 29 | USCS "Female Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 2 | Malignant Lung NeoplasmCancer | 55.9 | 55.6–56.3 | observed | #2 of 29 | USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349) | cdc-uscsObserved |
| 3 | Malignant Colon NeoplasmCancer | 34.5 | 34.2–34.7 | observed | #3 of 29 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 4 | Malignant Uterine Corpus NeoplasmCancer | 22.3 | 22.1–22.6 | observed | #4 of 29 | USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549) | cdc-uscsObserved |
| 5 | Non-Hodgkin LymphomaHematologic Malignancy | 16.7 | 16.5–16.9 | observed | #5 of 29 | USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood)) | cdc-uscsObserved |
| 6 | Cutaneous MelanomaCancer | 13.9 | 13.7–14.1 | observed | #6 of 29 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 7 | Malignant Ovarian NeoplasmCancer | 13.6 | 13.4–13.8 | observed | #7 of 29 | USCS "Ovary" (ICD-10 C56; ICD-O-3 C569) | cdc-uscsObserved |
| 8 | Malignant Thyroid Gland NeoplasmCancer | 13.1 | 12.9–13.3 | observed | #8 of 29 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 9 | Malignant Rectal NeoplasmCancer | 10.9 | 10.7–11.1 | observed | #9 of 29 | USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209) | cdc-uscsObserved |
| 10 | LeukemiaCancer Family | 10.5 | 10.4–10.7 | observed | #10 of 29 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 11 | Malignant Kidney NeoplasmCancer | 10.1 | 9.9–10.2 | observed | #11 of 29 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 12 | Malignant Pancreatic NeoplasmCancer | 10.1 | 10–10.3 | observed | #11 of 29 | USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259) | cdc-uscsObserved |
| 13 | Malignant Bladder NeoplasmCancer | 9.8 | 9.6–10 | observed | #13 of 29 | USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679) | cdc-uscsObserved |
| 14 | Malignant Cervical NeoplasmCancer | 8.4 | 8.3–8.6 | observed | #14 of 29 | USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539) | cdc-uscsObserved |
| 15 | Malignant Central Nervous System NeoplasmCancer | 5.9 | 5.7–6 | observed | #15 of 29 | USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729) | cdc-uscsObserved |
| 16 | Malignant Gastric NeoplasmCancer | 5 | 4.9–5.1 | observed | #16 of 29 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 17 | Multiple MyelomaHematologic Malignancy | 4.9 | 4.8–5 | observed | #17 of 29 | USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734) | cdc-uscsObserved |
| 18 | Malignant Liver NeoplasmCancer | 3 | 3–3.1 | observed | #18 of 29 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 19 | Hodgkin LymphomaHematologic Malignancy | 2.5 | 2.4–2.6 | observed | #19 of 29 | USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal)) | cdc-uscsObserved |
| 20 | Malignant Vulvar NeoplasmCancer | 2.4 | 2.3–2.4 | observed | #20 of 29 | USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519) | cdc-uscsObserved |
| 21 | Malignant Esophageal NeoplasmCancer | 2 | 2–2.1 | observed | #21 of 29 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 22 | Malignant Anal NeoplasmCancer | 1.7 | 1.6–1.8 | observed | #22 of 29 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
| 23 | Malignant Laryngeal NeoplasmCancer | 1.6 | 1.5–1.7 | observed | #23 of 29 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 24 | Malignant Salivary Gland NeoplasmCancer | 0.9 | 0.9–1 | observed | #24 of 29 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 25 | Malignant Vaginal NeoplasmCancer | 0.7 | 0.7–0.7 | observed | #25 of 29 | USCS "Vagina" (ICD-10 C52; ICD-O-3 C529) | cdc-uscsObserved |
| 26 | Malignant MesotheliomaCancer Family | 0.4 | 0.4–0.4 | observed | #26 of 29 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 27 | Malignant Hypopharyngeal NeoplasmCancer | 0.3 | 0.3–0.3 | observed | #27 of 29 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
| 28 | Malignant Nasopharyngeal NeoplasmCancer | 0.3 | 0.3–0.4 | observed | #27 of 29 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 29 | Kaposi SarcomaCancer | 0.1 | 0.1–0.1 | observed | #29 of 29 | USCS "Kaposi Sarcoma" (ICD-10 C46; ICD-O-3 histology 9140 (any site)) | cdc-uscsObserved |
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Trend
Mortality rate (age-standardized) — top 8 cancers, all years
Top cancers of 2003 (Female) traced over every year published for United States. Dashed lines mark estimated or projected values; the y axis starts at zero.
cdc-uscsObservedstandard: 2000 U.S. standard population (19 age groups)264 points
Clinical research
Clinical trial activity in United States
Registrant-entered study locations on ClinicalTrials.gov mapped to this country (any study type, any phase). A site is one location; a multi-site study weighs by its number of sites. Recruiting = location status RECRUITING, or the study status when the site has none.
- Sites
- 609,751
- Studies with a site here
- 50,884
- Recruiting sites
- 71,552
- Recruiting studies
- 7,740
Computed formula ci-trial-sites-v1 · source: clinicaltrials · shares are of sites, not of studies
Data updated 16 hours agoSource updated unknowntrial_site_country_counts
Regulatory
Oncology approval records · US
Records of the country's regulator as ingested (one record = one decision for one application or product identifier). Absence of a record here is not evidence of absence.
FDA · approved: 2,343 records / 304 drugs
- Sep 18, 2026Abemaciclib approved cancer not stated in this recordEfficacy supplement 2026-09-18 (see label)openfda
- Sep 9, 2026Aminolevulinic Acid approved cancer not stated in this recordEfficacy supplement 2026-09-09 (see label)openfda
- Sep 9, 2026Sevabertinib approved cancer not stated in this recordEfficacy supplement 2026-09-09 (see label)openfda
- Sep 4, 2026Camizestrant approved Malignant Breast Neoplasmin combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor…openfda
- Aug 28, 2026Ropeginterferon Alfa-2b approved cancer not stated in this recordEfficacy supplement 2026-08-28 (see label)openfda
- Aug 25, 2026Zanidatamab approved cancer not stated in this recordEfficacy supplement 2026-08-25 (see label)openfda
- Aug 25, 2026Tislelizumab approved cancer not stated in this recordEfficacy supplement 2026-08-25 (see label)openfda
- Jul 24, 2026Enzalutamide approved cancer not stated in this recordEfficacy supplement 2026-07-24 (see label)openfda
- Jul 24, 2026Enzalutamide approved cancer not stated in this recordEfficacy supplement 2026-07-24 (see label)openfda
- Jul 14, 2026Selpercatinib approved cancer not stated in this recordEfficacy supplement 2026-07-14 (see label)openfda
Regulatory
Provenance
Sources and freshness
What each source covers for this geography, exactly as ingested. Values are normalized (units, labels) but never changed.
| Source | Metric | Sex | Years | Cancers | Estimate types | Standard population | Ingested |
|---|---|---|---|---|---|---|---|
| cdc-uscs | Incidence rate (age-standardized) | Both | 1999–2023 (25) | 24 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-uscs | Incidence rate (age-standardized) | Female | 1999–2023 (25) | 29 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-uscs | Incidence rate (age-standardized) | Male | 1999–2023 (25) | 27 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-uscs | Mortality rate (age-standardized) | Both | 1999–2024 (26) | 23 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-wonder | Mortality rate (age-standardized) | Both | 2018–2024 (7) | 36 | observed | 2000 U.S. Std. Population | 2026-09-08 |
| cdc-uscs | Mortality rate (age-standardized) | Female | 1999–2024 (26) | 28 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-wonder | Mortality rate (age-standardized) | Female | 2018–2024 (7) | 36 | observed | 2000 U.S. Std. Population | 2026-09-08 |
| cdc-uscs | Mortality rate (age-standardized) | Male | 1999–2024 (26) | 26 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-wonder | Mortality rate (age-standardized) | Male | 2018–2024 (7) | 36 | observed | 2000 U.S. Std. Population | 2026-09-08 |
| cdc-uscs | New cases | Both | 1999–2023 (25) | 32 | observed | — | 2026-09-08 |
| cdc-uscs | New cases | Female | 1999–2023 (25) | 29 | observed | — | 2026-09-08 |
| cdc-uscs | New cases | Male | 1999–2023 (25) | 27 | observed | — | 2026-09-08 |
| cdc-uscs | Deaths | Both | 1999–2024 (26) | 31 | observed | — | 2026-09-08 |
| cdc-wonder | Deaths | Both | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-uscs | Deaths | Female | 1999–2024 (26) | 28 | observed | — | 2026-09-08 |
| cdc-wonder | Deaths | Female | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-uscs | Deaths | Male | 1999–2024 (26) | 26 | observed | — | 2026-09-08 |
| cdc-wonder | Deaths | Male | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-wonder | Mortality rate (crude) | Both | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-wonder | Mortality rate (crude) | Female | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-wonder | Mortality rate (crude) | Male | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortalitylicense: approvedUS Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- CDC WONDER — Underlying Cause of Death (US mortality by ICD-10 site)license: approvedUS Government work (public domain) subject to CDC WONDER data use restrictions (statistical reporting only; counts ≤ 9 must not be published; no re-identification)
Age-standardized rates use the 2000 U.S. standard population (19 age groups); they are not comparable with rates standardized to the World (Segi) population used by IARC. Global comparisons are not available: the IARC Global Cancer Observatory remains under license review and the SEER API awaits credentials (CLAUDE.md §10.3-10.4). Only geographies with licensed observations get a page; see /countries.
Data updated 22 days agoSource updated 1999–202410,680 observations approx. · ranks from snapshots geo=USA